ContinuingEducationCE

Page 14 / New Jersey AIDSLine, Summer 2015

ConclusionIn this article, we have summarized vaccination recommenda-tions for HIV-infected infants, children, adults, and adults >65 years of age. Immunization with attenuated and live vaccines are an integral part of the health care maintenance of all HIV-infected persons and have led to significant reductions in in-fectious disease morbidity and mortality. However, coverage has not reached the 90% goals as outlined in the Center for Disease Control’s Healthy People 2020 initiative.91 This age-specific review of vaccines should help providers become in-creasingly comfortable with recommended vaccinations among HIV-infected persons of all ages.

Summary Tables

Vaccines for HIV-infected infants and children ages 0-6 yearsHAV 2 dose series in second year of life

HBVa,b 3 dose series in first year of life

Influenza Inactivated Vaccinec 1 dose annually

Pneumococcal Conjugate Vaccine (PCV13)d

4 dose series in infants

Pneumococcal Polysaccharide Vaccine (PPSV23)

1 dose age ≥2 years, 8 weeks after PCV13

DTaP 5 dose series

MMRe 2 dose series in second year of life

VZVe 2 dose series in second year of life

NOTES. a Can use Engerix-B or RecombivaxHB, vaccines are interchangeable. b If non-immune 1 month after completion of series, repeat 3 dose

primary series once. c Children 6 months to 8 years of age who were previously not immunized

against influenza, should receive 2 doses at least 4 weeks apart. d If 14-71 months old and completed series with PCV 7, give one

supplemental dose of PCV 13. e If meets CD4 % and/or cell count as outlined in text.

Vaccines for HIV-infected children and adolescents ages 7-18 yearsHAV 2 dose series if not vaccinated

HBVa,b 3 dose series if not vaccinated

HPV 3 dose series

Influenza Inactivated Vaccine 1 dose annually

Pneumococcal Conjugate Vaccine (PCV13)

1dose

Pneumococcal Polysaccharide Vaccine (PPSV23)

2 doses max, 5 years apart

Tdap 1 dose TdaP age 11-12

MMRc 2 doses if no evidence of immunity

VZVc 2 doses if no evidence of immunity

NOTES. a Can use Engerix-B or RecombivaxHB, vaccines are interchangeable. b If non-immune repeat 3 dose primary series once. c If meets CD4 % and/or cell count as outlined in text.

Vaccines for HIV-infected adult ages 19-64 yearsHepatitis Aa

Hepatitis Bb

Td every 10 years

Tdap once in adulthood as substitute for Td

Inactivated Influenza annually

Pneumococcal Polysaccharide Vaccine (PPSV23)

1-2 doses, 5 years apart

Pneumococcal Conjugate Vaccine (PCV13)

once in adulthood

MMRc

Human Papillomavirusd

NOTES. a 2 dose series if no evidence of immunity. b 3 dose series if no evidence of immunity. c If meets CD4 % and cell count as outlined in text. d Recommended through age 26.

Vaccines for HIV-infected Adults Age >65 yearsHepatitis Aa

Hepatitis Bb

Td every 10 years

Tdap once if not done 19-64 years

Inactivated Influenza annually

Pneumococcal Polysaccharide Vaccine (PPSV23)

once

Pneumococcal Conjugate Vaccine (PCV13)

once if not done 19-64 years

MMRc

NOTES. a 2 dose series if no evidence of immunity. b 3 dose series if no evidence of immunity. c If meets CD4 % and cell count as outlined in text.